Fulcrum Therapeutics (FULC) grants 57,000 options to accounting chief

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. reported a stock option grant to its Principal Accounting Officer, Greg Tourangeau. On February 2, 2026, he received a stock option (right to buy) covering 57,000 shares of common stock at an exercise price of $10.72 per share.

The option is scheduled to vest in equal quarterly installments over four years, beginning on the vesting commencement date of January 1, 2026, contingent on his continued service on each vesting date. Following this grant, he beneficially owns 57,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tourangeau Greg

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.72	02/02/2026		A		57,000		(1)	02/01/2036	Common Stock	57,000	$0.00	57,000	D

Explanation of Responses:

1. This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.

	/s/ Gregory Tourangeau	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Fulcrum Therapeutics (FULC) disclose in this Form 4 filing?

Fulcrum Therapeutics disclosed a stock option grant to Principal Accounting Officer Greg Tourangeau. He received options for 57,000 shares at an exercise price of $10.72 per share, vesting quarterly over four years starting January 1, 2026, subject to continued service.

How many stock options were granted to Greg Tourangeau at Fulcrum Therapeutics (FULC)?

Greg Tourangeau was granted stock options covering 57,000 shares of Fulcrum Therapeutics common stock. These options vest in equal quarterly installments over four years from a January 1, 2026 commencement date, assuming he continues in service on each applicable vesting date.

What is the exercise price of the new Fulcrum Therapeutics (FULC) stock options?

The new stock options granted to Greg Tourangeau have an exercise price of $10.72 per share. This means he can purchase up to 57,000 shares of Fulcrum Therapeutics common stock at $10.72 once the options vest over the four-year schedule.

How do the Fulcrum Therapeutics (FULC) options to Greg Tourangeau vest?

The options granted to Greg Tourangeau vest in equal quarterly installments over four years. Vesting begins on the commencement date of January 1, 2026, and each installment requires his continued service with Fulcrum Therapeutics on the relevant vesting dates.

What is Greg Tourangeau’s role at Fulcrum Therapeutics (FULC) in this Form 4?

Greg Tourangeau is identified as an officer of Fulcrum Therapeutics, serving as Principal Accounting Officer. The Form 4 reports a stock option grant to him, reflecting equity-based compensation tied to his ongoing service with the company over a four-year vesting period.

How many derivative securities does Greg Tourangeau own after this Fulcrum Therapeutics (FULC) grant?

After the reported transaction, Greg Tourangeau beneficially owns 57,000 derivative securities, all held directly. These represent stock options giving him the right to buy Fulcrum Therapeutics common shares at $10.72 per share, subject to the quarterly vesting schedule described.